Stay updated with breaking news from Ivir. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) hit a new 52-week low on Thursday after Morgan Stanley lowered their price target on the stock from $27.00 to $15.00. Morgan Stanley currently has an equal weight rating on the stock. Vir Biotechnology traded as low as $13.16 and last traded at $13.41, with a volume […]
Vir Biotechnology (NASDAQ:VIR – Get Free Report) had its target price lowered by Barclays from $59.00 to $41.00 in a research note issued to investors on Friday, FlyOnTheWall reports. Barclays‘s price objective suggests a potential upside of 222.83% from the stock’s current price. Other analysts have also recently issued reports about the company. Needham & […]
Vir Biotechnology (NASDAQ:VIR – Get Free Report) had its target price decreased by equities researchers at Barclays from $59.00 to $41.00 in a research report issued to clients and investors on Friday, FlyOnTheWall reports. Barclays‘s price target points to a potential upside of 222.83% from the company’s current price. A number of other equities research […]
Vir Biotechnology Inc. said Thursday a mid-stage trial of a treatment for symptomatic flu failed to meet its main goals, sending the stock down 40%...
VIR | Complete Vir Biotechnology Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.